146 related articles for article (PubMed ID: 27359083)
1. Therapeutic targeting of Toll-like receptors: a review of Toll-like receptors and their signaling pathways in psoriasis.
Rahmani F; Rezaei N
Expert Rev Clin Immunol; 2016 Dec; 12(12):1289-1298. PubMed ID: 27359083
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.
Gilliet M; Conrad C; Geiges M; Cozzio A; Thürlimann W; Burg G; Nestle FO; Dummer R
Arch Dermatol; 2004 Dec; 140(12):1490-5. PubMed ID: 15611427
[TBL] [Abstract][Full Text] [Related]
4. Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells.
Meng Y; Wang M; Xie X; Di T; Zhao J; Lin Y; Xu X; Li N; Zhai Y; Wang Y; Li P
Int J Mol Med; 2017 May; 39(5):1101-1110. PubMed ID: 28339016
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod.
Ueyama A; Yamamoto M; Tsujii K; Furue Y; Imura C; Shichijo M; Yasui K
J Dermatol; 2014 Feb; 41(2):135-43. PubMed ID: 24387343
[TBL] [Abstract][Full Text] [Related]
6. Cathelicidin Antimicrobial Peptide LL37 Induces Toll-Like Receptor 8 and Amplifies IL-36γ and IL-17C in Human Keratinocytes.
Miura S; Garcet S; Li X; Cueto I; Salud-Gnilo C; Kunjravia N; Yamamura K; Gonzalez J; Murai-Yamamura M; Rambhia D; Krueger JG
J Invest Dermatol; 2023 May; 143(5):832-841.e4. PubMed ID: 36496195
[TBL] [Abstract][Full Text] [Related]
7. Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.
Lai CY; Su YW; Lin KI; Hsu LC; Chuang TH
J Immunol Res; 2017; 2017():7807313. PubMed ID: 28894754
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy.
Rácz E; Prens EP
Expert Rev Mol Med; 2009 Dec; 11():e38. PubMed ID: 20003607
[TBL] [Abstract][Full Text] [Related]
9. Proinflammatory effect of high-mobility group protein B1 on keratinocytes: an autocrine mechanism underlying psoriasis development.
Zhang W; Guo S; Li B; Liu L; Ge R; Cao T; Wang H; Gao T; Wang G; Li C
J Pathol; 2017 Feb; 241(3):392-404. PubMed ID: 27859256
[TBL] [Abstract][Full Text] [Related]
10. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
11. Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin.
Begon E; Michel L; Flageul B; Beaudoin I; Jean-Louis F; Bachelez H; Dubertret L; Musette P
Eur J Dermatol; 2007; 17(6):497-506. PubMed ID: 17951129
[TBL] [Abstract][Full Text] [Related]
12. TLR activation pathways in HIV-1-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
[TBL] [Abstract][Full Text] [Related]
13. Selective control of type I IFN induction by the Rac activator DOCK2 during TLR-mediated plasmacytoid dendritic cell activation.
Gotoh K; Tanaka Y; Nishikimi A; Nakamura R; Yamada H; Maeda N; Ishikawa T; Hoshino K; Uruno T; Cao Q; Higashi S; Kawaguchi Y; Enjoji M; Takayanagi R; Kaisho T; Yoshikai Y; Fukui Y
J Exp Med; 2010 Apr; 207(4):721-30. PubMed ID: 20231379
[TBL] [Abstract][Full Text] [Related]
14. Toll-Like Receptor-Mediated Upregulation of CXCL16 in Psoriasis Orchestrates Neutrophil Activation.
Steffen S; Abraham S; Herbig M; Schmidt F; Blau K; Meisterfeld S; Beissert S; Guck J; Günther C
J Invest Dermatol; 2018 Feb; 138(2):344-354. PubMed ID: 28942364
[TBL] [Abstract][Full Text] [Related]
15. Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle.
Farkas A; Kemény L
Int Immunopharmacol; 2012 Jun; 13(2):215-8. PubMed ID: 22522054
[TBL] [Abstract][Full Text] [Related]
16. S1PR4 Signaling Attenuates ILT 7 Internalization To Limit IFN-α Production by Human Plasmacytoid Dendritic Cells.
Dillmann C; Ringel C; Ringleb J; Mora J; Olesch C; Fink AF; Roberts E; Brüne B; Weigert A
J Immunol; 2016 Feb; 196(4):1579-90. PubMed ID: 26783340
[TBL] [Abstract][Full Text] [Related]
17. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells.
Gautier G; Humbert M; Deauvieau F; Scuiller M; Hiscott J; Bates EE; Trinchieri G; Caux C; Garrone P
J Exp Med; 2005 May; 201(9):1435-46. PubMed ID: 15851485
[TBL] [Abstract][Full Text] [Related]
18. Suppressive effect of β,β-dimethylacryloyl alkannin on activated dendritic cells in psoriasis by the TLR7/8 pathway.
Wang Y; Zhao J; Di T; Wang M; Ruan Z; Zhang L; Xie X; Meng Y; Lin Y; Liu X; Wang N; Li P
Int Immunopharmacol; 2016 Nov; 40():410-418. PubMed ID: 27697724
[TBL] [Abstract][Full Text] [Related]
19. Targeting IL-17 with ixekizumab in patients with psoriasis.
Dyring-Andersen B; Skov L; Zachariae C
Immunotherapy; 2015; 7(9):957-66. PubMed ID: 26569072
[TBL] [Abstract][Full Text] [Related]
20. Epidermal barrier reaction to an in vitro psoriatic microenvironment.
Donetti E; Cornaghi L; Arnaboldi F; Ricceri F; Pescitelli L; Maiocchi M; Carriero F; Baruffaldi Preis F; Prignano F
Exp Cell Res; 2017 Nov; 360(2):180-188. PubMed ID: 28890293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
